Diabetes Mellitus News and Research RSS Feed - Diabetes Mellitus News and Research

Diabetes mellitus is a severe and debilitating chronic disease that develops in nearly 5 percent of the world’s population. People with this disease have a shortage of insulin or a reduced ability to use insulin, the hormone regulating blood glucose levels, which is normally produced by the pancreas. In the United States alone, an estimated 18 million people have diabetes, and each year about 1 million Americans are diagnosed with the disease. It is the sixth leading cause of death in the US and is responsible for over 200,000 deaths a year. Insulin-dependent (type I) diabetes accounts for around 10% of diabetics. For those patients, suffering from an inability of their pancreas to produce insulin, the only practical treatment possible is regular insulin replacement by multiple daily injections. Transplantation of a pancreas or pancreatic tissue would be beneficial to millions of such patients in that it would restore their normal ability to produce self insulin. Transplantation of human pancreas or pancreatic islets is a practiced and time-honored such therapeutic approach, but is extremely limited by the severe shortage of human donor organs. Tissera's R&D efforts in this domain are directed towards the development of a universally available and reliable source of animal fetal donor pancreatic precursor tissue, suitable for transplantation and eventual normal structural and functional growth in human diabetics.
Better management of blood sugar, blood pressure and LDL-cholesterol levels could reduce cardiovascular risk

Better management of blood sugar, blood pressure and LDL-cholesterol levels could reduce cardiovascular risk

While controlling blood pressure, blood sugar and LDL-cholesterol levels reduces the risk of cardiovascular disease in people with diabetes, only 7 percent of diabetic participants in three major heart studies had recommended levels of these three factors, according to research from the Heart Disease Prevention Program at the University of California, Irvine School of Medicine. [More]
Increased consumption of antibiotics in childhood may lead to adolescent prediabetes

Increased consumption of antibiotics in childhood may lead to adolescent prediabetes

Young children who take antibiotics may disrupt their gut's microbial ecosystem and be more likely to develop prediabetes in adolescence, new research from Greece reports. The study results will be presented in a poster Sunday, April 3, at ENDO 2016, the annual meeting of the Endocrine Society, in Boston. [More]
Study: Age and gender affects prevalence of certain peripheral vascular diseases

Study: Age and gender affects prevalence of certain peripheral vascular diseases

New findings from large-scale studies of more than 3.6 million people who underwent screening for cardiovascular disease reveals that a person's age and gender affects the prevalence of certain types of peripheral vascular diseases (PVD), and that diabetes is a major risk factor for developing these diseases, even in patients without heart disease. [More]
Preventing blindness through portable eye examinations: an interview with Dr Mario Ettore Giardini

Preventing blindness through portable eye examinations: an interview with Dr Mario Ettore Giardini

The number of blind people is high. In 2010, the World Health Organisation estimated that, throughout the world, approximately 39 million people are blind. [More]
Scientists explore new strategies to prevent onset of type 1 diabetes

Scientists explore new strategies to prevent onset of type 1 diabetes

Type 1 diabetes affects 30,000 individuals throughout Germany and is the most common metabolic disease in children and adolescents. To halt the ever-increasing incidence, the young investigator group "Immunological Tolerance in Type 1 Diabetes" at the Institute of Diabetes Research directed by Prof. Dr. Anette-Gabriele Ziegler is exploring new strategies to prevent the onset of the disease. [More]
Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

Orexigen Therapeutics, Inc. today announced Valeant Pharmaceuticals International, Inc. will commercialize Mysimba (naltrexone HCl / bupropion HCl prolonged release) in Central and Eastern Europe. [More]
Renal risk factors for NA-treated HBV patients identified

Renal risk factors for NA-treated HBV patients identified

A South Korean research team has identified several clinical and medical factors associated with renal function decline in patients with chronic hepatitis B virus infection treated with oral nucleos(t)ide analogues. [More]
Resistance to prior antiviral agents impacts TDF response

Resistance to prior antiviral agents impacts TDF response

Taiwanese researchers find that virological response to tenofovir disoproxil fumarate in treatment-experienced patients with chronic hepatitis B virus infection can vary depending on the nucleos(t)ide analogue the patient is resistant to. [More]
CPAP appears to improve glycemic control in patients with OSA and type 2 diabetes

CPAP appears to improve glycemic control in patients with OSA and type 2 diabetes

Continuous positive airway pressure, or CPAP, appears to improve glycemic control in patients with obstructive sleep apnea and type 2 diabetes that is not well controlled, according to research published in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine. [More]
ACC, AHA support implementation of proposed cardiovascular measures, with reservations

ACC, AHA support implementation of proposed cardiovascular measures, with reservations

Quality measures announced today by the Core Quality Measures Collaborative represent a step forward in reducing paperwork and confusion while also allowing providers to focus on measures that impact patient outcomes, the American College of Cardiology (ACC) and the American Heart Association (AHA) said in support of implementation of the proposed cardiovascular measures. But the groups expressed reservations about blood pressure targets included in the measures. [More]
Study sheds light on role of red raspberries in metabolically-based chronic diseases

Study sheds light on role of red raspberries in metabolically-based chronic diseases

Components in red raspberries may have anti-inflammatory, anti-oxidative and metabolic stabilizing activity, according to a comprehensive review of the available scientific literature published in the January issue of Advances in Nutrition. [More]
Study reveals association between DNA methylation and type 2 diabetes

Study reveals association between DNA methylation and type 2 diabetes

Researchers from the Hospital del Mar Medical Research Institute have found an epigenetic mechanism implicated in the regulation of blood sugar. The study, published in the journal Molecular Human Genetics, reveals that the methylation of the TXNIP gene is associated with diabetes mellitus type 2 and, in particular, average blood glucose levels. [More]
Height affects risk of major non-communicable diseases

Height affects risk of major non-communicable diseases

Height is largely genetically determined, but in recent decades the height of children and adults has steadily increased throughout the world: In adulthood the children are almost always significantly taller than their parents. [More]
Cistus extracts attack HIV and Ebola viruses

Cistus extracts attack HIV and Ebola viruses

Scientists at the Helmholtz Zentrum München discover that extracts of the medicinal plant Cistus incanus (Ci) prevent human immunodeficiency viruses from infecting cells. Active antiviral ingredients in the extracts inhibit docking of viral proteins to cells. Antiviral activity of Cistus extracts also targets Ebola- and Marburg viruses. [More]
Lupin Pharmaceuticals releases Metformin HCl ER Tablets

Lupin Pharmaceuticals releases Metformin HCl ER Tablets

Pharma Major Lupin Limited announced today that its US subsidiary, Lupin Pharmaceuticals Inc., has launched its Metformin HCl ER Tablets, 500 mg and 1000 mg to market a generic equivalent of Santarus Inc.'s Glumetza HCl ER Tablets, 500 mg and 1000 mg. [More]
Vascular risk factors implicated in normal pressure hydrocephalus

Vascular risk factors implicated in normal pressure hydrocephalus

Researchers have found that vascular risk factors are associated with idiopathic normal pressure hydrocephalus and could be a possible target for intervention. [More]
Artificial pancreas moves closer to becoming a reality

Artificial pancreas moves closer to becoming a reality

As the accuracy, reliability, adoption, and successful use of Continuous Glucose Monitoring (CGM) continue to increase, the ultimate goal of combining CGM with an insulin pump and sophisticated algorithms for automating the control and suspension of insulin infusion--known as the "artificial pancreas"--moves closer to becoming a reality. [More]
Post-term deliveries associated with increased short-term risks to newborns

Post-term deliveries associated with increased short-term risks to newborns

While pregnancy is considered full-term at 40 weeks, only some 5 percent of women actually give birth on their predetermined due date. Most OBGYNs recommend more frequent and more vigilant monitoring after 40 weeks and sometimes the artificial induction of labor. But many pregnant women refuse induction due to the risk of stress to the fetus or increased likelihood of requiring a caesarean section. [More]
UCA researchers create new animal models to study link between diabetes and Alzheimer's disease

UCA researchers create new animal models to study link between diabetes and Alzheimer's disease

In recent time, many epidemiological studies have proved very close links existing between diabetes and Alzheimer´s disease. In fact, it has been stated that diabetes is a significant risk factor for suffering from Alzheimer and vascular dementia, the two main causes of dementia. [More]
ß-Hydroxybutyrate LiquiColor® reagent system to detect ketosis

ß-Hydroxybutyrate LiquiColor® reagent system to detect ketosis

Stanbio Laboratory, an EKF Diagnostics company, has developed the ß-Hydroxybutyrate LiquiColor® Reagent System to improve the detection of clinically significant ketosis. [More]
Advertisement